We thank Drs. Zheng and Wang for their comments ([@B1]) regarding fibroblast growth factor 23 (FGF23) compared with serum phosphorus concentration for prediction of mortality in the African American--Diabetes Heart Study (AA-DHS). Mildly elevated mean serum phosphorus concentrations and calcium-phosphorus products, well within their normal ranges, are cardiovascular disease risk factors and predict death in populations without chronic kidney disease (CKD) ([@B2],[@B3]). The AA-DHS cohort permitted investigation of novel and conventional risk factors for cardiovascular disease and mortality in those with recent African ancestry at increased risk based upon the presence of type 2 diabetes ([@B4]). AA-DHS participants did not have advanced nephropathy at recruitment (median \[25th, 75th percentile\] estimated glomerular filtration rate 91.3 \[76.4, 111.3\] mL/min/1.73 m^2^), permitting analyses with low likelihood of confounding from CKD. Although Zheng and Wang ([@B1]) state that "serum phosphorus is the main stimulus for FGF23 secretion," regulation of FGF23 is a complex and incompletely understood process, particularly in the earliest stages of CKD ([@B5]). With the exception of patients with end-stage kidney disease, serum phosphorus concentrations have not shown immediate and consistent effects on the secretion of FGF23 ([@B5]).

We performed additional analyses to address their questions on the effects of serum phosphorus and the calcium-phosphorus product on mortality in the AA-DHS ([@B4]). The median \[25th, 75th percentile\] levels of serum phosphorus and calcium-phosphorus product were 3.6 \[3.2, 3.9\] mg/dL and 33.8 \[30.4, 37.7\] mg/dL, respectively. Distributions were not statistically different between those who died and those still alive for both serum phosphorus levels (3.6 \[3.2, 3.9\] vs. 3.5 \[3.1, 3.8\] mg/dL; *P* = 0.24) and calcium-phosphorus product (33.9 \[30.6, 37.8\] vs. 32.3 \[28.4, 36.1\] mg/dL; *P* = 0.07). In contrast, strong differences were observed for plasma FGF23 levels in those alive versus those who died (107.3 \[79.0, 154.0\] vs. 162.3 \[97.3, 362.0\] RU/mL; *P* = 5 × 10^−5^). FGF23 was weakly correlated with serum phosphorus and calcium-phosphorus product in these participants (*r* = 0.17 and 0.15, respectively; both *P* \< 0.01). Adjusting for age, sex, and African ancestry proportion in a multivariate analysis, as was performed for FGF23 (see Table 3 in Chan et al. \[[@B4]\], models 1 and 2), serum phosphorus and calcium-phosphorus product were not significant predictors of mortality in the AA-DHS. We observed hazard ratios for mortality of 0.91 (95% CI 0.69, 1.21) and 0.82 (0.62, 1.10) for serum phosphorus and calcium-phosphorus product, respectively (*P* \> 0.15 in both). In the fully adjusted models, the hazard ratios were 0.80 (95% CI 0.59, 1.09) for serum phosphorus and 0.74 (0.54, 1.02) for calcium-phosphorus product; *P* values were 0.16 and 0.06, respectively.

A total of 508 AA-DHS participants had both FGF23 and serum phosphorus measurements, and 54 deaths were recorded during a median 6.6-year follow-up. In contrast, the Cholesterol And Recurrent Events (CARE) study that assessed serum phosphorus and mortality in individuals with prior myocardial infarctions had better power ([@B2]); CARE included 4,127 individuals (136 African American) with 375 deaths during a 5-year follow-up.

In conclusion, plasma FGF23 significantly predicted mortality in the AA-DHS, whereas serum phosphorus and the calcium-phosphorus product did not. These results support use of FGF23 to predict mortality in African Americans with type 2 diabetes who lack nephropathy.
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